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  The c-Fes protein is a structurally unique non-receptor protein-tyrosine kinase encoded 
by the fes/fps proto-oncogene and is expressed in myeloid hematopoietic, vascular endothelial, 
and some epithelial and neuronal cell types. Downstream of a number of cytokines and growth 
factors, c-Fes plays a role in regulation of cell growth, differentiation, and chemotaxis. 
Dysregulation of c-Fes activity is implicated in a number of cancers, including acute 
myelogenous leukemia (AML) and some renal carcinomas. Structurally, c-Fes includes an 
amino-terminal F-BAR region—consisting of a Fes/CIP4 homology (FCH) domain and the first 
of two coiled-coil motifs (CC1)—followed by CC2 and the carboxy-terminal Src homology 2 
(SH2) domain closely linked to a typical bilobate kinase domain (KD).  
Unlike its oncogenic retroviral orthologs (v-Fes/Fps), c-Fes kinase activity is tightly 
regulated in vivo, yet lacks known negative regulatory features common to other cytoplasmic 
tyrosine kinases, such as a SH3 domain or regulatory tail tyrosine. In fact, a c-Fes truncation 
containing only the SH2 and KD is constitutively active which suggests a possible auto-
inhibitory role for the unique N-terminal region. Deletion and mutation experiments reveal that 
loss of the predicted CC1 structure leads to upregulation similar to the c-Fes SH2-KD truncation.  
This would be the first case of autoinhibition by the coiled-coil; however, it is still unclear how 
the F-BAR acts in cis to accomplish autoinhibition. Substitution of the native c-Fes SH2 with 
that of v-Src (but not homologous v-Fps) displays an uninhibited catalytic activity level 
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analogous to the CC1 mutant, suggesting interdomain interaction between the F-BAR and 
SH2/KD may contribute to an inactive conformation. I collected evidence for this mechanism 
and began to develop tools to define the putative F-BAR:SH2 interface utilizing the bimolecular 
fluorescence complementation (BiFC) technique. Demonstrated by BiFC in 293T cells, the F-
BAR interacts with the SH2 domain in a CC1-dependent manner. It may be that CC1 forms a 
critical interface with αB of the SH2 as preliminary data suggest that v-Src-mimetic mutations in 
αB weaken CC1-SH2 recognition. Further characterization of the specific intramolecular 
interactions involved in c-Fes regulation would advance new paradigms in modular domain 
relationships and could expand cancer drug discovery efforts. 
 v 
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1.0  C-FES TYROSINE KINASE 
In a distinct and small subfamily of the non-receptor protein-tyrosine kinome, the human 
c-fes/fps proto-oncogene encodes the unique c-Fes tyrosine kinase (1, 2). Though identified 
originally as the human homolog of transforming retroviral oncoproteins (3), c-Fes catalytic 
activity is finely tuned to certain cell-surface signaling pathways in vivo (discussed in section 
1.3). The N-terminal region, making up over 55% of the protein, is a distinctive feature of c-Fes. 
At this end is a Fes/CIP4 Homology (FCH) region followed by two coiled-coil homology 
domains which have essential roles in the regulation of kinase activity and mediate c-Fes 
oligomerization in vivo (discussed in sections 1.2 and 1.3). Together the FCH and CC1 domains 
define an FCH-Bin/Amphiphysin/Rvsp (F-BAR) domain (see section 1.2.1). At the C-terminal 
end is a Src homology 2 (SH2) domain associated with the kinase domain. Examination of the 
crystal structure of the SH2 closely associated with the kinase domain has elucidated the 
mechanism of positive regulation of the kinase domain (discussed in section 1.3.1). Over the 
following five chapters, this dissertation reviews the characteristics of the Fes gene, protein 
structure, catalytic regulation, biological function, and role in disease. 
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1.1 CHARACTERIZATION OF THE C-FES GENE 
1.1.1 Discovery and cloning of retrovirus and human genes. 
On region 2, band 6, sub-band 1 of the long arm of the human chromosome 15 is c-fes, a 
13.2 kb stretch that encodes a discrete member of the Fes/Fer subfamily (4). Initially, fes DNA 
was isolated as a transforming oncogene cloned from avian (v-fps, Fujinami) and feline (v-fes, 
Gardner-Arnstein [GA], Snyder-Theilen [ST], and Hardy-Zuckerman) sarcoma retroviruses (5-
8). Several research groups in the first half of the 1980s independently identified the human gene 
(c-fes) by its high degree of sequence homology to the viral (v-fes/fps) oncogenes (3, 9-11). The 
sequence of the human c-fes gene was first reported by Roebroek et al. in 1985 and consists of 
19 exons. The sequence revealed a translation start site in exon 2 and the translation stop codon 
(TGA) within exon 19, 200 bp upstream of a poly(A) site (12). 
1.1.2 Sequence and structural homology with viral oncogene. 
Despite significant sequence homology, human c-Fes is non-transforming and displays 
restricted catalytic activity, whereas the transforming v-Fes/Fps viral orthologs exhibit 
constitutive tyrosine kinase activity (2, 13-15). The overall structural organization of mammalian 
(c-Fes) and avian (c-Fps) orthologs are the same: an N-terminal unique region (F-BAR), 
including at least two coiled-coil domains, central SH2 domain, and C-terminal kinase domain. 
Shown in Figure 1 (below c-Fes) are the structures of three Fes-homologous oncoproteins: (top 
down) the Fujinami avian sarcoma virus v-Fps followed by the Gardner-Arnstein and Snyder-
Theilen feline variants. In all three, the predominant structural modification is an N-terminal-
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fused viral Gag sequence (3, 16-18). The fes gene in the feline viral strains lacks various exons 
that encode for N-terminal features like CC1 or CC2 in ST and GA, respectively. Any one or a 
combination of these structural variations could account for the activation of the kinase, not to 
mention more subtle changes and mutations. Transformation studies with mutant and chimeric 
constructs (discussed later) address these possibilities (18-22). 
 
Figure 1. Structural aspects of c-Fes and viral oncogene homologs. From amino- to carboxyl-terminus: c-Fes is 
made up of an N-terminal F-BAR domain, which is composed of a FesCIP4 homology (FCH) domain and a coiled-
coil (CC1), a second coiled-coil (CC2), a Src homology 2 (SH2) domain, and a bilobed tyrosine kinase domain. 
Homologous viral oncogenes v-fps and v-fes have viral gag sequences fused upstream of sequences derived from 
cellular genes. Below mammalian c-Fes, descending: v-Fps from Fujinami avian sarcoma virus, v-Fes from 
Gardner-Arnstein feline sarcoma virus, and v-Fes from Snyder-Theilen feline sarcoma virus. (Not drawn to scale or 
with true orientation of all features.)  
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1.1.3 c-fes gene region features. 
The whole 13.2 kb human c-fes gene (15.q26.1) encompasses 19 exons (Figure 2). Exon 
1 is noncoding, the site of transcription initiation (discussed above). The translational start site is 
found within exon 2, which encodes the N-terminal FCH domain. The first coiled-coil is encoded 
by exons 4 and 5, while exon 8 codes for the second. The central SH2 domain is coded for by 
exons 11 and 12 followed by exons 13 through 19 encoding the catalytic domain. Exon 19 
harbors the translation stop codon (TGA) and a downstream polyadenylation signal. (12) 
 
Figure 2. Major features of c-fes gene. The c-fes gene is arranged as 19 exons. The noncoding (black) 1st exon 
holds the transcription initiation site (arrow). Exon 2 (green) encodes the FCH domain. Exons 4-5 (green) encode 
CC1. Exon 8 (gray) encodes CC2. Exons 11-12 (red) encode the SH2 domain. Exons 13-19 (blue) encode the 
tyrosine kinase domain. The remainder of exon 19 is noncoding since it harbors the translation termination codon 
and poly(A) addition site.  
The c-fes locus is a self-contained genetic element, containing all the necessary 
transcription regulatory elements in a space of 446 bp and tissue-specific promoters in less than 2 
kb of 5’- and 3’-flanking sequences (23-25). In the c-fes promoter, 72-83 bp upstream of the 3’ 
end of exon 1, there are two major transcription initiation sequences (26, 27). Having more than 
one initiation site can occur in cases where TATA box or Inr (initiator) sequences are lacking 
(28-30), like with c-Fes. The entire promoter is defined as -425/+91 from the first initiation site 
(+1), where the core promoter for the transcription initiation complex is located at -131/+91 (25, 
31). Within this critical core promoter there is one fes expression factor (FEF; 5’-GAATCA-3’), 
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two hematopoietic-specific PU.1/Spi-1 (5’-AGGAA-3’), and three Sp1 (5’-CCGCCC-3’) 
recognition sites (25, 32). The Sp1 transcription factor is ubiquitously expressed transcription 
factor Sp1 (25). While FEF and PU.1/Spi-1 factor expression is tissue-specific, mutation of their 
recognition sequences drastically reduces c-fes promoter activity in reporter gene assays (25, 32). 
Such studies suggest these transcription factors are critical to c-fes expression.  
In terms of negative regulation of c-fes transcription, a region within intron 1 has been 
identified by deletion analyses (26). Reporter gene expression was halved when suppressed by 
this regulatory element (26). Southwestern and DNA footprinting analyses of K-562 myeloid cell 
nuclear extracts reveal the negative regulatory region localized to a 14 bp span starting at 
position +441 (5’-TGCGTGTGAGCGAG-3’). Interestingly, this sequence is homologous to 
Interleukin-3 gene negative regulatory elements (26, 33). 
1.2 STRUCTURE OF THE C-FES PROTEIN 
 Human c-Fes (UniProtKB P07332) is an 822 amino acid (93 kDa) cytoplasmic protein 
that is made up of an N-terminal F-BAR domain (FCH and CC1), a second coiled-coil, and a C-
terminal SH2 domain closely linked to a kinase domain (see Figure 1). It lacks an SH3 domain, a 
pleckstrin homology (PH) domain, or a negative regulatory tail tyrosine, which are common 
modular domains in other non-receptor tyrosine kinases (e.g. Abl, Src, Tec/Btk, and Zap70). The 
unique region of Fes/Fer is on the N-terminal end, upstream of the SH2. (1, 2, 15, 34) 
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1.2.1 F-BAR region. 
The FCH domain component of the F-BAR is not found in other non-receptor protein 
tyrosine kinases, although originally named for Fes and Cdc42-interacting protein (CIP4) 
homology (35). Many FCH-containing proteins are adaptors associated with endocytosis, 
vesicular transport, and cytoskeletal remodeling (36). Due to these trends, it has been proposed 
that the c-Fes FCH domain has some role in microtubule dynamics. Indeed, FCH domain 
deletion results in loss of murine Fes co-localization with microtubule nucleation sites and 
abolished microtubule nucleation (37). Furthermore, reintroduction of Fes into Fes-deficient 
MEFs rescued the aberrant microtubule and centrosome phenotype. Later, it was shown that the 
FCH domain mediated interaction with tubulin monomers, which might suggest c-Fes facilitates 
tubulin polymerization in vivo (38).  
Adjacent to c-Fes FCH domain is the first of two predicted coiled-coil domains (39, 40). 
A coiled-coil is a super-helical bundle of several parallel or antiparallel amphipathic α-helices 
coiled together (41). The α-helices consist of heptad repeats of amino acids arrayed in a pattern 
where every first and fourth residues form a hydrophobic interface, while the rest are 
hydrophilic, forming a solvent-exposed surface. In the superhelix, a hydrophobic sidechain packs 
into space shielded by the four surrounding hydrophilic residues like “knobs into holes” (41). 
There is evidence that coiled-coils are involved in numerous biological activities including 
protein oligomerization and scaffolding (42).  
Previous work from our lab strongly implicates the c-Fes coiled-coil domains in the 
regulation of Fes oligomerization and kinase activity. When wild-type c-Fes is expressed in 
COS-7 cells, it is catalytically repressed and for the most part displays a diffuse cytoplasmic 
distribution. In striking contrast, a c-Fes CC1 point mutant (L145P) exhibits greatly elevated 
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catalytic activity and microtubular localization. This finding suggests that CC1 (and the F-BAR) 
may play a role in regulation of kinase domain activity.  
Together, the FCH and CC1 domains comprise the F-BAR domain. Proteins in the F-
BAR domain family are often  at the cell membrane acting as multi-functional adapters involved 
in processes like endocytosis and cell motility (36).  
There is no published literature on the X-ray crystal structure of the c-Fes F-BAR 
domain, (see Appendix A) however it is likely to be very similar to F-BAR domain subfamily 
members like Fer and FCHSD1/2 (43). Homology modeling of the Fes F-BAR domain to FBP17 
(44) identified conserved basic residues (R113/K114) implicated in binding phosphoinositides. 
In vitro, the F-BAR domain indeed binds phosphoinositides unless the conserved basic residues 
are mutated to uncharged residues, such as glutamine (45). In mast cells expressing the RK-QQ 
Fes mutant, FcepsilonRI-induced Fes tyrosine phosphorylation and Lyn-containing membrane 
fraction localization was defective (45).  
1.2.2 CC2 and linker region.  
Coiled-coil 2 follows CC1, but is separate from the F-BAR domain. This second coiled-
coil may be important for oligomerization, but identical mutations in CC1 and CC2 have vastly 
different effects on kinase activity (22, 46). Like in oligomer transactivation, CC2 may help 
recruit other activators or substrates of Fes. For example, the transcriptional co-repressor KRAB-
associated protein (KAP)-1 was pulled out of Fes CC2-baited yeast two-hybrid screens (47). 
Follow-up experiments in yeast demonstrated that KAP-1 interacts with c-Fes, and in Sf-9 cells 
the KAP-1 coiled-coil domain is sufficient for binding with the Fes N-terminal unique region. 
HL-60 myeloid leukemia cells express Fes and KAP-1 endogenously and the two were found in 
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association in that context. Finally, in human embryonic kidney cells, full length Fes and KAP-1 
co-expression resulted in both Fes autophosphorylation and phosphorylation of KAP-1 tyrosine 
residues, suggesting KAP-1 may be both an activator and downstream effector of Fes. (47) 
The CC2-SH2 linker is over 92 amino acids in length (48). Largely disordered, apart 
from a few predicted helices and a turn, this linker is probably flexible to accommodate trans 
interactors (substrate, adapters, etc.) and perhaps permit cis interactions between the features of 
the unique N-terminal region and the downstream SH2-kinase core. 
1.2.3 SH2 domain. 
Found in hundreds of proteins, SH2 domains are conserved signaling modules that 
recognize specific phosphotyrosine peptide sequences in order to mediate signal transduction 
(49-51). Phosphopeptide library screens, biophysical, biochemical, and genetic studies on the 
selectivity of SH2 domains for their phosphotyrosine substrates revealed that binding affinity can 
be attributed to the phosphate moiety of the target, while residues within two to six positions 
from that phosphotyrosine usually determine specificity (52-58). Recruitment of effectors by the 
SH2 domains of cytokine and growth factor receptors has been extensively characterized, but 
these modular domains were actually discovered in non-receptor tyrosine kinases like Fes (50). 
The v-Fps SH2 was one of the first described and shown to be necessary for full kinase activity 
(59) and substrate recognition (60). Like in viral Fps, the c-Fes SH2 domain plays a dual role in 
modulation of kinase activity and biological impact. In vitro Fes substrate phosphorylation and 
autophosphorylation are significantly impaired by deletion of the SH2 domain (61, 62). In vivo, 
substitution of the whole Fes SH2 with that of v-Src results in greatly upregulated Fes kinase 
activity (21). Together, these studies implicate the c-Fes SH2 domain function in both positive 
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and negative regulation of kinase activity. Unlike Src family kinases, the c-Fes SH2 domain is 
disengaged from the kinase domain in inactive Fes. This way the SH2 domain may be more 
accessible to other Fes domains, adapters, or substrates. 
The close proximity of the SH2 and kinase domains prompted the idea that the two may 
interact in cis to bring about a more stable active kinase domain. Such speculation is consistent 
with the fact that mild proteolysis of v-Fps generates a stable SH2-kinase domain core fragment 
that highly active. Confirming the positive regulatory role of the SH2, mutations that affect 
kinase function likewise affect the SH2-kinase domain interaction (62, 63). X-ray 
crystallography provides direct evidence for the regulatory interaction of the c-Fes SH2 and 
kinase domains, revealing a helical interface between the SH2 domain and the N-terminal lobe of 
the kinase domain (64). More detail on this follows in section 1.3.1; refer to Figure 3. 
In addition to c-Fes kinase domain regulation, an intact SH2 domain is also required for 
biological function. The c-Fes/v-Src SH2 chimera localizes to focal adhesions in transformed 
rodent fibroblasts (21), which suggests that a shift in subcellular localization may influence its 
catalytic activity (or vice versa) and the SH2 may influence both localization and catalysis. 
Additionally, wild-type c-Fes exhibits association and phosphorylation at focal adhesions, acting 
on p130 Cas and other macrophage focal adhesion proteins (65). The same is true in epithelial 
cells where the interacting partner and substrate is Ezrin, an adapter protein involved in 
membrane-cytoskeleton attachment (66), where the Fes SH2 domain recognizes Ezrin pTyr477. 
This relationship is necessary for HGF-induced cell scattering. In COS cells transfected with 
active mutants of c-Fes, the SH2 domain mediates association of Fes with the tubulin 
cytoskeleton (38). In vitro without any accessory proteins, purified recombinant c-Fes 
phosphorylates purified tubulin and catalyzes tubulin polymerization (38). Altogether, these data 
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support the idea that c-Fes regulates microtubule dynamics by phosphorylation and interactions 
dependent on its SH2 domain. 
 
Figure 3. Crystal Structure of c-Fes SH2-kinase domain core. The full c-Fes SH2-kinase unit (amino acids 448-
822) is shown on the left (PDB: 3BKB). The helical interface of the SH2 (red) and kinase (blue) domains is enlarged 
on the right. Interaction of the αA helix of the SH2 domain and the αC helix of the kinase domain N-lobe is 
stabilized by the SH2 E469 contacting the αC R609, maneuvering the αC helix into a pro-catalytic conformation. 
Salt bridging between K590 and E607 further stabilizes the primed state. The side chain of the activation segment 
(purple) autophosphorylation site, Y713, is also shown. Mutational analysis verified that both tight packing and 
electrostatic interactions shown are crucial for this stable, pro-catalytic form of the SH2-kinase core. (64) 
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1.2.4 Kinase domain. 
Localized to the C-terminal region of c-Fes is a typical bilobed tyrosine kinase domain. 
(Refer to Figure 3, above.) This domain is comprised of 261 amino acids (561-822), including a 
highly conserved lysine (K590) within the ATP-binding pocket and the autophosphorylation site 
(Y713). (1, 67) The pTyr713 is located on the activation loop and is required for full activation 
of the kinase domain (61, 68), much like c-Src Y416 (69). This autophosphorylation aids in 
stabilization of the activation segment in its catalysis-competent conformation. Unlike some 
other non-receptor tyrosine kinase domains, Fes lacks a membrane-targeting signal (e.g. Abl 
myristate binding site) or regulatory tail (e.g. Src pY530).  
Helix αC is located on the N-lobe of the kinase domain and forms a helical interface with 
the SH2 (discussed later). Cooperation of key residues, phosphotyrosines, a-loop, substrate, and 
SH2 domain achieves the most efficient kinase. Mutation or loss of any of these critical features 
can affect the enzymatic function of the kinase domain. Catalytically, the kinase domain 
coordinates phosphate transfer from ATP onto the target tyrosine sidechain acceptor: ATP + 
[protein]-L-tyrosine = ADP + [protein]-L-tyrosine phosphate. Reported substrates include BCR 
(70), HCLS1/HS1 (45), PECAM1 (71), STAT3 (72, 73), TRIM28 (47), tubulin (38), as well as 
Fes molecules (autophosphorylation). Fes kinase domain activity is implicated in several cellular 
functions discussed in section 1.4.3. 
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1.3 REGULATION OF C-FES ACTIVITY 
Wild-type c-Fes catalytic activity is precisely regulated in vivo unlike the retroviral 
oncoproteins. Phosphoamino acid analyses of c-Fes immunoprecipitated from cells following 
metabolic labeling with 32PO4 provided the first evidence of this phenomenon (74). Consistent 
with a complete lack of c-Fes autophosphorylation, no phosphotyrosine was detectable; only 
phosphoserine was found. The same conclusions were drawn with Rat-2 fibroblast 
transformation assays. Even when expressed to high levels, c-Fes was not sufficient to transform 
rodent fibroblasts (13). Transforming activity of c- Fes was not reported until exceedingly over-
expressed in NIH 3T3 cells (14). The exact conformation adopted by full-length c-Fes when 
inactive or active, monomeric or oligomeric, wild-type or mutant is not known. What is known 
about c-Fes regulation provides the basis for hypothetical models. 
1.3.1 Positive regulation by the SH2:Kinase domain interaction. 
There are multiple modular domains comprising c-Fes, however the most proximal to the 
kinase domain is the SH2 domain. Several studies suggest that the central SH2 domain regulates 
c-Fes kinase activity. En bloc substitution of the Fes SH2 domain with variants results in altered 
Fes kinase activity: upregulation in the case of v-Src SH2 or downregulation with Ras-GAP SH2 
(21, 46). Partial proteolysis of homologous v-Fps releases a stable, highly active 45 kDa core 
protein containing only the SH2 and kinase domains, which supports SH2-kinase domain 
interaction is necessary and sufficient for full kinase activity (61-63). The X-ray crystal structure 
of the stable, active c-Fes SH2-kinase unit shows that the SH2 domain sits atop the kinase 
domain, structurally organizing and stabilizing the kinase domain for activity. For example, the 
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critical α-helix C is packed close with αA of the SH2 domain (64). Accordingly, mutation of key 
residues solved in the SH2:kinase interface abrogates kinase activity. All the above findings 
support the notion that the SH2 domain is a positive regulator of c-Fes activity. 
There is no crystal structure of full-length c-Fes, but the high-resolution structure of the 
SH2 domain and adjacent kinase domain from the Knapp group reveals many details of the 
active SH2-kinsae domain complex (64). Confirming previous reports that the SH2 domain 
positively regulates kinase activity, the crystal structure displays extensive, tight packing of the 
SH2 against the N-lobe of the kinase domain. Unlike the c-Abl or c-Src kinases, c-Fes has a 
short SH2-kinase linker and a glycine residue (G463) that allow for the close association of SH2 
and kinase domains. This is stabilized by interdigitation and electrostatic interactions. SH2 αA 
helix glutamate residues (E469/472) interact with an arginine (R609) in the αC of kinase domain 
(see Figure 3), stabilizing the αC helix in a favorable orientation for communication (E607-
K590) with a lysine in the active site. Thus the kinase domain is set for enzymatic activity. As 
predicted, mutation at these key sites can result in loss of both SH2-kinase domain interaction 
and catalytic activity. Predicted to hamper packing of the SH2 against kinase domain N-lobe, 
G463V abrogated kinase activity of the full-length Fes. Likewise, E to K mutation at 469 and 
472 diminished kinase activity as there was not the SH2 salt bridge network with the N-lobe. Co-
crystallization of the Fes SH2-kinase core with a substrate peptide demonstrated how substrate 
binding further stabilizes the activation-loop by inducing a β-sheet between the substrate peptide 
and activation-loop, cooperatively strengthening SH2:kinase N-lobe interaction and the active 
conformation. (64) 
Supporting the role of the SH2 substrate recruitment in promoting catalytic activity, loss 
of SH2-ligand interaction resulted in loss of the SH2:kinase domain interaction, rendering the αC 
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helix highly mobile. Accordingly, abolishing phosphotyrosine binding by a point mutation in the 
SH2 domain greatly diminished Fes kinase activity in a cell-based assay. Therefore, it is 
reasonable to envision that a series of coordinated events is needed for induction of c-Fes kinase 
activity (see Figure 4). In the inactive state, the activation loop is disordered, helix αC is not 
engaged with the SH2 helix A, no substrate ligand is bound to the SH2 domain and Y713 is 
unphosphorylated. Substrate recruitment by the SH2 domain induces stable interaction with the 
kinase domain and positions αC for enzymatic activity. Then the primed kinase domain 
autophosphorylates, further stabilizing the activation loop, thus the kinase domain assumes the 
fully active state. 
 
 
Figure 4. Model of c-Fes SH2, kinase domain, and substrate in concert during activation. I) In its least stable 
form, the SH2 is unligated and Y713 is unphosphorylated. The Fes SH2 domain (red), αC (dark blue), and activation 
loop (purple) of the kinase domain (light blue) remain disordered and inactive. II) Recognition of phosphorylated 
substrate (yellow) by the SH2 domain induces structural ordering (white arrows) of the SH2, stabilization of 
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SH2:KD interface, and rotation of αC into an orientation primed for activity (white arrow). Autophosphorylation of 
Y713 stabilizes the a-loop and is required for the fully active form. (64)  
1.3.2 Oligomerization. 
As discussed previously, the coiled-coil oligomerization motifs were suspected to 
mediate Fes oligomerization. Experimentally, deletion of the unique N-terminal region 
eliminated Fes oligomerization, while deletion of the SH2 and kinase domains did not alter the 
Fes oligomer profile (40). Gel filtration analyses of lysates derived from cells expressing full-
length Fes revealed that active c-Fes was exclusively oligomeric and could form 
homopentameric complexes. Based on in vitro data (22, 46), the coiled-coil oligomerization 
domains mediate conversion of c-Fes between inactive monomers and active oligomers in one 
possible regulatory model (Figure 5). In this model, CC1 interacts with CC2 and holds c-Fes in 
an inactive monomeric state. When the negative regulatory CC1 domain no longer restrains CC2, 
c-Fes forms oligomers and undergoes autophosphorylation, achieving full activation. 
Transactivation in homo-oligomers would ramp up the response. A major difficulty with this 
model is since it is largely based on in vitro studies excluding the SH2 and kinase domains. Later 
studies showed that it was possible that wild-type c-Fes also forms constitutive oligomers (75, 
76), which does not support a model in which c-Fes is a monomer in its inactive state. As it turns 
out, c-Fes forms oligomers in live cells independently of its activation status as demonstrated by 
BiFC (76). These data suggest that some other regulatory mechanism, rather than 
oligomerization, controls c-Fes activity in vivo. 
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 Figure 5. Cartoon of activation by oligomerization of c-Fes. A model for the regulation of c-Fes activity where 
CC1 interacts intramolecularly with CC2 in order to prevent oligomerization and activation. When CC1 no longer 
binds CC2 (perhaps by competitive binding with an upstream effector), c-Fes is free to form oligomers by CC2 
dimerization. This drives autophosphorylation and transactivation to produce fully active, oligomeric Fes. (Dimer 
shown for simplicity. Cartoon not drawn to scale or with true orientation of all features.) While this model provides 
an attractive explanation for the role of coiled-coils in kinase regulation, subsequent studies have shown that c-Fes 
forms constitutive oligomers in cells regardless of its activation state. Thus, an alternative mechanistic explanation is 
required. This older model also ignores the positive impact of the SH2 domain on the kinase domain. 
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1.3.3 Autophosphorylation. 
The major site of autophosphorylation in human c-Fes maps to Y713 (61, 68, 77). A 
phenylalanine substitution at this position, which lacks a hydroxyl group on the aromatic ring, 
abolishes autophosphorylation there. Even with an ideal substrate in vitro, Fes-Y713F substrate 
phosphorylation is less than 10% that of wild-type (61). Since Fes pY713 levels correlate so 
strongly with downstream Fes target phosphorylation and biological function, it is a reliable 
readout of Fes kinase activation. Later sections discuss the regulation of autophosphorylation and 
the role it plays in promoting full kinase activation. 
1.3.4 Models of c-Fes downregulation. 
Older biochemical and mutagenesis studies suggested a model of Fes regulation in which 
activity was controlled by interconversion of monomeric and oligomeric states. Gel filtration and 
cross-linking studies showed that Fes oligomerization depends on both CCs, while only loss of 
CC1 activates Fes (22, 76). Based on these, it was proposed that inactive, monomeric c-Fes was 
restrained by intramolecular CC1-CC2 binding. It was only a CC2 unhindered by CC1 that could 
mediation formation of active oligomers. However, subsequent BiFC studies showed that c-Fes 
forms oligomers irrespective of activation state in vivo and even oligomerization-defective Fes 
mutants exhibit transphosphorylation (76). While it is clear that CC1 plays an important role in 
downregulation of Fes kinase activity, the mechanism by which this occurs is not clear. 
As described in previous sections, X-ray crystallography supports a mechanism for 
upregulation of Fes kinase activity via the cooperation of SH2 and kinase domains in assuming a 
stable, enzymatically active form. The difficulty in crystallizing full-length c-Fes and the 
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deficiency of structural data outside of the C-terminal SH2-kinase unit leaves the suggestions of 
other data as the foundation for models of c-Fes downregulation. The most salient observations 
are these: i) deletion or disorder of the CC1 domain results in strong activation of the kinase 
domain (22, 75), which supports an allosteric or intramolecular-interaction mechanism 
connecting the N-terminal F-BAR region and C-terminal SH2-kinase region of c-Fes; ii) en bloc 
substitution of the c-Fes SH2 domain with that of v-Src, but not v-Fps, also results in strong 
activation of the kinase domain (21). A model that explains these findings is that the F-BAR and 
SH2 domains interact to restrain SH2-dependent kinase activation. It could be proposed that the 
F-BAR domain competitively interacts with the SH2 or kinase domain at or near the SH2-kinase 
domain interface. It is also possible that the F-BAR domain binds elsewhere on the SH2 or 
kinase domain and by binding either alters the conformation of one partner’s SH2-kinase domain 
interface or keeps the two physically separated by reorienting one partner to prevent the 
interaction. Kinase activation may then be permitted in this model by interaction of the N-
terminal segment with cellular binding partners (47, 78), relieving its influence on SH2 or kinase 
domain and permitting the formation of the active SH2-kinase structure. In order to support this 
model with evidence, one must identify specific features of c-Fes that are required for the F-
BAR:SH2/kinase domain interaction. (Discussion continued in sections 3 and 4.)  
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1.4 BIOLOGICAL FUNCTIONS OF C-FES 
1.4.1 Expression pattern. 
Where a protein is expressed plays a part in determining the functional role of that 
protein. There are many different tissues and cell types, each with their own unique complement 
of expressed gene products available for interaction. In the case of a kinase, what substrates are 
available and what happens to them after being phosphorylated is important. Over murine 
development, the expression pattern of c-Fes becomes more specific. In an adult, the c-Fes 
kinase is expressed in a discrete subset of tissues including myeloid hematopoietic, vascular 
endothelial, neuronal, and epithelial cells where it responds to cytokine and growth factor stimuli 
[reviewed in (2, 15)]. In mice, endogenous murine fes and transgenic human c-Fes are localized 
to the bone marrow, lymph system, spleen and lungs (23). In mouse embryos, fes is expressed in 
the vascular endothelium, skin epidermis, and ventricular linings in the brain (79). In situ 
hybridization and Northern blot analysis detected c-fes transcripts in liver, lung, skin, spinal 
cord, heart, gut and kidney (80). Diseased tissues may still express c-Fes, at normal levels or 
higher, while others may lose Fes expression. For example, in many cases of acute myeloid 
leukemia (AML) c-fes is highly expressed (81, 82). However, c-Fes expression is robust in 
normal colonic epithelial tissue and lost or diminished in tumor tissue from the same individual 
(83). The role of c-Fes in cancer is complex, and is covered in more detail below. 
 19 
1.4.2 Subcellular distribution. 
Like the tissues that make up an organism, the various cellular compartments, organelles, 
and cytostructural networks that a protein can be localized to are important to biological 
function. This subcellular localization may be tissue- or cell-specific or change as the greater 
organism advances through stages of development. Like human development, individual proteins 
are “born” from a ribosomal complex and are trafficked through a life cycle that may stop at the 
membrane, nucleus, or even outside the cell. In the case of c-Fes, it is predominantly localized to 
the cytoplasm in the downregulated state (21, 38). In a few cell types, c-Fes displays a diffuse 
cytoplasmic distribution with a perinuclear bias and some punctate projections that spread 
towards the cell membrane (79). A minority of publications report a c-Fes subpopulation that is 
nuclear in myeloid hematopoietic tissue, despite lacking any known nuclear localization 
sequence (84, 85).  
The subcellular localization of c-Fes also appears to be activation-dependent. In Rat-2 
cells, ectopic c-Fes displays a diffuse cytoplasmic distribution that shifts to focal adhesions when 
active (21). Activation of c-Fes coincides with relocalization from a diffuse cytoplasmic 
distribution to microtubules in COS-7 and neuronal cells (37, 86). In macrophages, c-Fes 
associates with the actin cytoskeleton (65). A unique activation-dependent relocalization event 
occurs in LLC-PK1 porcine kidney cells where activated c-Fes move between focal adhesions 
and cell-to-cell contact points depending on confluency (66). 
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1.4.3 Proliferation and differentiation. 
Being the cellular homolog of viral oncoproteins, the implication is that c-Fes plays a role 
in growth and differentiation (2). Normal expression in myeloid hematopoietic tissue and 
involvement in certain leukemias suggests that c-Fes functions in hematopoiesis (87-89). Fes is 
implicated in signal transduction downstream of some hematopoietic cytokines and growth 
factors like granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) 
and erythropoietin (85). However, it is not a perfectly clear case. When kinase-dead Fes was 
overexpressed in a couple growth factor-dependent cell-lines, TF-1 and 32D, proliferation in 
response to GM-CSF and IL-3, and the differentiation program induced by G-CSF were not 
altered (90). It may be a cell-line-specific result, but Fes catalytic activity is not critical for 
growth and differentiation in response to GM-CSF and IL-3 in these cells. Yet, the closely 
related kinase Fer is pervasively expressed (91) and may play redundant role (92). If the 
overexpressed phosphorylation-defective Fes does not overwhelm it, Fer may be sufficient in 
this case. That said, c-Fes null and knockout mice exhibited some cases of defect, but it is clear 
that c-Fes is not essential in innate immunity (2, 93). Naturally, differentiation varies in how it is 
manifested in different tissue lineages. However, c-Fes is involved in a few general biological 
activities as part of its cell- or signal-specific proliferation or differentiation function. 
As discussed previously, c-Fes undergoes a subcellular redistribution to the cytoskeleton 
upon kinase activation in various cell types [Rat-2 to focal adhesions (21), COS-7 (37) & 
neuronal cells (86) to microtubules]. Rat-2 and COS cells do not normally express Fes, but 
ectopically expressed Fes exhibits concomitant activation and relocalization. In neuronal cells, 
endogenous c-Fes co-precipitates with soluble tubulin in whole cell lysates of neonatal rat brain 
and immunofluorescence microscopy shows endogenous c-Fes co-localizes with microtubule 
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fibers in cultured rat neurons (77). Based on these facts, c-Fes may function in regulating cellular 
architecture and motility. Along those lines, TF-1 cells expressing active c-Fes mutants undergo 
GM-CSF-independent cell attachment and spreading (75). It may be that wild-type c-Fes 
regulates microtubule dynamics in response to these cellular signals (37). When activated, c-Fes 
may catalyze both tubulin phosphorylation and polymerization, and then by the SH2 domain 
come into association with tyrosine-phosphorylated microtubules for recruitment to other 
substrates. It’s possible that pTyr-tubulin Fes-SH2 recruitment is accomplished by other tyrosine 
kinases like c-Src. In fact, co-expression of c-Fes with an active mutant of the Hck stimulates Fes 
relocalization to microtubules in COS cells (38). Furthermore, endogenous c-Fes has been 
observed associating with the tubulin cytoskeleton without need for introduction of an active 
mutant SFK (37). Lastly, c-Fes was found aggregating at the microtubule organizing center and 
colocalized with γ-tubulin, which is essential for microtubule nucleation and orientation, when 
microtubular networks are damaged by demecolcine-treatment in COS cells. A naturally 
occurring event that disrupts microtubular networks is mitotic metaphase. Interestingly, active 
mutant FesL145P co-localizes with the mitotic spindle (38). Taken all together, the above 
evidence implicates c-Fes in cytoskeletal dynamics, especially microtubules.  
Several lines of evidence support a role for c-Fes in angiogenesis, the complex process 
that leads to the development of new blood vessels. First, expression levels of endogenous c-Fes 
in primary human vascular endothelial cells are comparable to myeloid cell levels (24). Second, 
the angiogenic growth factors FGF-2 and angiopoietin-2 stimulate c-Fes activity in capillary 
endothelial cells. In the same cell type, simply over-expressing c-Fes is sufficient for chemotaxis 
and tubulation (94). In fact, such over-expression induces tube formation independent of FGF-2. 
Lastly, transgenic mice expressing a membrane-targeted, activated mutant of Fes were 
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hypervascular and developed hemangiomas (24). Consistent with these observations, c-Fes is 
implicated in angiogenesis. 
1.5 PATHOLOGICAL ROLES OF C-FES 
 
Figure 6. Possible modes of c-Fes involvement in oncogenesis. Depending on the type of cell and the type of 
cancer, Fes may be related to tumorigenesis in several ways: I) activated mutant upstream, like a ligand-independent 
receptor; II) Fes overexpression (there are no known activated mutants of Fes in human cancer); III) overexpression 
or over-activity of downstream targets that required Fes signaling; IV) support of tumor angiogenesis; V) loss of Fes 
expression or tumor suppression activity. Gain-of-function/expression (left): AML, renal carcinoma, breast cancer 
(IV). Loss-of-function/expression (right): CML, colorectal cancer.  
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1.5.1 Oncogenesis. 
Human c-Fes is homologous to several retroviral oncoproteins named for their sarcoma-
forming ability. The only major difference between the well-behaved c-Fes and the oncogenic 
viral products is an N-terminal gag derived from the virus. Given that c-Fes is strictly regulated, 
it stands to reason that uncontrolled Fes activity can be pathological. When those problems 
involve proliferation and differentiation, then the stage is set for oncogenesis. Indeed, extreme 
overexpression (14), viral gag fusion (19), or activated mutants of Fes (21, 75) alone are all 
sufficient for robust tyrosine kinase activity and fibroblast transformation (20, 95). Knockdown 
by siRNA targeting c-fes significantly slows renal carcinoma cell proliferation (96). Stable 
expression of activated mutant Fes in the TF-1 myeloid leukemia cell line, which normally 
requires media supplemented with GM-CSF, drives cytokine-independent cell growth and 
survival (75). However, wild-type c-Fes at endogenous levels can also contribute to oncogenesis. 
In acute myelogenous leukemia (AML) blasts and cell lines, c-Fes is an essential effector 
downstream from an activated mutant of the FLT3 receptor (97). Similarly, the ligand-
independent activated mutant KIT(D816V) required c-Fes for cell survival and proliferation (98).  
These data are consistent with other clinical findings that implicate Fes (99), even in an ancillary 
role in the tumor niche (100).  
1.5.2 Tumor suppression. 
In addition to an oncogenic role for Fes, evidence also suggests that c-Fes may be 
involved in tumor suppression in some cell types (101). In chronic myelogenous leukemia 
(CML) cell lines, ectopic expression of c-Fes resulted in differentiation and suppressed cell 
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growth (102, 103). Bcr-Abl, the fusion protein primarily responsible for initiation of chronic 
phase CML, is then a potential target for c-Fes. Interestingly, Bcr-Abl protein levels drop in cells 
stably expressing c-Fes (77). Nucleotide sequence analysis of the tyrosine kinome in 182 
colorectal cancer cell lines and xenografts identified c-fes along with only five others for 
consistently exhibiting kinase domain mutations (104). These kinase domain mutations (M704V, 
R706Q, V743M, and S759F) reduce or eliminate c-Fes enzymatic activity (83). In another 
epithelial tissue, Fes delays tumor onset in a mouse model of breast cancer, as onset is more 
rapid in mice with either null or kinase-dead fes mutations, while expression of a fes transgene 
rescues the slower tumor onset kinetics observed in c-fes null mice (101). Likewise, HT-29 and 
HCT 116 colorectal cancer cell line growth in soft agar is suppressed by Fes (83). While c-Fes is 
abundantly expressed in matched normal colonic epithelial cells from CRC patient tissue 
samples, expression is reduced or absent in the majority of colon tumor sections from the same 
group of individuals (83). The observations that Fes mutations associated with colorectal cancer 
decrease kinase activity, and that Fes gene expression is often silenced in colorectal tumors, 
suggest that Fes may play a tumor suppressor role in cancers of epithelial origin.  
 25 
2.0  BIMOLECULAR FLUORESCENCE COMPLEMENTATION 
Biochemical complementation has been in use since the mid-20th century. It was not until 
the turn of the millennium that a fluorescent protein was engineered for complementation assays 
(105). Shortly after, Hu et al. were the first to publish a fluorescence complementation study in 
live cells, with YFP, and named the technique Bimolecular Fluorescence Complementation 
(106). In this technique, cells are transfected with expression constructs encoding the two 
interacting molecules of interest, one which is fused to the N-terminal fragment of the Venus 
variant of YFP (VN) and the other to a complementary C-terminal fragment (VC). Importantly, 
these fragments do not fluoresce alone, nor do they interact and refold on their own (106, 107). 
Once expressed, interacting molecules bring the two non-fluorescent fragments into close 
proximity where they refold into the fluorescent protein (complementation). This stable 
reconstituted fluorescent protein emits a readily measured fluorescent signal indicative of the 
interaction (108), as pictured below in Figure 7. 
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 Figure 7. Bimolecular fluorescence complementation. Potential interacting partners (Fes domains in this 
example) are fused to non-fluorescent N-terminal (1-173) and C-terminal (155-238) fragments of the Venus YFP 
variant coding sequence (termed “VN” and “VC” respectively) and co-expressed in the same cell. If the domains 
interact, VN and VC are brought into close proximity, resulting in structural complementation and YFP 
fluorescence.  (Not drawn to scale or with true orientation of all features.) 
2.1 METHODOLOGY 
 In the BiFC approach, interacting partners (c-Fes domains in this case) are fused to non-
fluorescent amino- and carboxyl-terminal segments of the Venus YFP coding sequence and co-
expressed in the same cell. Interaction draws YFP fragments into close proximity, and then the 
two must refold into the native β-barrel structure in order to reconstitute a fluorophore capable of 
reporting the interaction by emission. The tertiary structure of the coupled fragments is highly 
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stable, so the interactions captured will be visible if there are enough formed. Images captured of 
the cells expressing the BiFC pair can be analyzed and quantified. Common to all protein–
protein interaction assays, it is critical to identify suitable controls and parameters which identify 
and limit non-specific interactions and false positives. Ideally, controls include specific 
mutations that eliminate or severely reduce the interactions of interest. (109) It is also possible 
add untagged competitors to the experiment as a control. 
2.2 ADVANTAGES 
BiFC offers a useful, adaptable technique to directly examine protein-protein interaction 
in a more physiologically relevant environment. Conventional complementation, where the 
protein reporter divided into two non-functional fragments is usually an enzyme of some kind, 
usually involves a more complicated reporting method. BiFC combines the simplicity of a 
complementation assay with the power to visualize and quantify the fluorescent intensity and 
subcellular distribution in cells. Since the fragment folding is virtually irreversible, given enough 
expression time BiFC is sensitive enough to detect even transient interactions between proteins 
expressed at physiological levels (106, 110). BiFC is also versatile as there are many fluorescent 
proteins to work with. BiFC can be obtained between fragments of  Aequorea variants (CFP, 
GFP, and YFP) and Anthozoa or Discosoma red-shifted proteins (mCherry). (109) Thus the 
spectrum of fluorescence excitation and emission wavelengths is broad.  In the case of YFP, 
engineers are attempting to optimize refolding through mutation, e.g. Venus (111). The enhanced 
complementation efficiency allows for experiments to be performed at 37°C, compatible with 
culture conditions for most mammalian cells (112, 113) Reducing the need to treat the cells in 
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unusual or harsh ways can increase efficiency and validity. For example, protein complexes can 
be identified by biochemical approaches like co-immunoprecipitation, but these invariably 
involve cell lysis and often lack temporal and subcellular resolution. With BiFC, the investigator 
can directly view interaction in live cells. Additionally, untagged competitors that may disrupt 
the protein–protein interaction can only prevent the earliest onset of BiFC after association 
begins, suggesting that this first phase is relatively short (half-time of seconds to minutes) and 
again largely irreversible thus trapping even transiently formed complexes (106). Thus it is 
possible for BiFC to detect more binding events like SH3 domain and ligands. Fluorescence 
resonance energy transfer (FRET) techniques are also applicable in PPI studies. In contrast, 
BiFC involves relatively simple measurements with a single excitation/emission (unless you opt 
for multicolor BiFC with non-overlapping excitation/emission spectra). In contrast to FRET, 
BiFC is more tolerant of the relative orientation of the distinct tags while retaining comparable 
distance constraints (114). BiFC signals are appropriate for analysis by advanced imaging 
techniques and high-content analysis. One can even expand investigation to more than two 
protein partners using multicolor BiFC or BiFC combined with FRET. 
2.3 APPLICATION 
Generally, BiFC is utilized in protein-protein interaction studies. Basically, complexes 
are visualized in cells, but combined with complementary techniques and controlled variables 
BiFC can be information rich. For example, BiFC followed by comparative mutagenesis of the 
suspected dimerization interface may be used to delineate features of the site of interaction (115, 
116). BiFC has been applied to a wide variety of complexes in numerous cell types (115). Many 
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interactions assessed by BiFC have been relatively stable ones, such as transcription factor 
dimerization (117), ubiquitin modifications (118), or association between Akt and Smad3 (119). 
Some have undertaken high-content BiFC, like in quantifying 7TM receptor signaling 
recruitment of β-arrestin2 (109). In this case, BiFC provided data consistent with the dual sensor 
model of β-arrestin binding to 7TM receptors (120). In the Smithgall lab, Fes oligomerization 
(76) and Nef dimerization (121) have been studied in a BiFC context. The possibilities for this 
tool grow with each new designer fluorescent reporter, new techniques to enhance or couple with 
BiFC, and as new questions are asked and answered. 
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3.0  A NOVEL ROLE FOR THE UNIQUE N-TERMINAL REGION IN THE AUTO-
REGULATION OF C-FES 
3.1 BACKGROUND AND SIGNIFICANCE 
High levels of c-Fes are found in myeloid leukemias, presumably representing expansion 
of a c-Fes-positive cell population (26, 74, 99). Although active c-Fes can be transforming, 
ectopic expression of wild-type c-Fes in fibroblasts does not result in transformation. The 
activity of full-length c-Fes is tightly regulated in vivo, with the catalytic domain assuming an 
inactive state (13) Crystal structure analysis revealed that specific association of the SH2 and 
kinase domain is critical to the maintenance of the active state (64). In cells, the 45 kDa SH2-
kinase domain unit is highly active, suggesting the N-terminal unique region restrains this 
coupling. The crystal structure of full-length c-Fes has not been reported and it is not known 
what (if any) interactions may exist between the N-terminal F-BAR domain and the SH2-kinase 
domain. That said, consideration of the activities of Fes SH2 and F-BAR domain mutants 
support a model in which F-BAR interaction with the SH2 domain may act to repress kinase 
activity (Figure 8). 
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 Figure 8. Activating and inactive mutants of Fes. The tight regulation of c-Fes kinase activity can be overcome in 
multiple ways as summarized here. N-terminal fusion of viral Gag sequences generates a chimeric protein with 
robust tyrosine kinase and transforming activities in fibroblasts (19, 20, 95). Possibly, viral Gag fusion impedes 
negative autoregulation and/or relocalizes Fes to a subcellular compartment (e.g., plasma membrane, cytoskeleton) 
essential for Fes signaling. However, myristoylation and plasma membrane targeting alone are insufficient for fully 
active Fes kinase in cells (21, 22), Targeting of c-Fes to focal adhesions by substitution of the native SH2 domain 
with that of v-Src results in stimulation of the kinase (21). Similarly, mutagenesis or deletion of the first coiled-coil 
domain in the F-BAR causes drastic upregulation of Fes kinase activity, and the mechanism by which this N-
terminal modification impacts the C-terminal kinase domain is not clear yet. A possible explanation is laid out in 
this dissertation. 
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3.2 HYPOTHESIS 
3.2.1 The F-BAR domain plays a key role in autoinhibition of c-Fes kinase activity 
through specific interactions with the SH2 domain. 
 Since structural and mutational analyses of c-Fes reveals that the specific association of 
the SH2 and kinase domain is critical to the maintenance of the active state (2, 51, 64) and the 
SH2-kinase unit is active in cells while full-length wild-type c-Fes is not, this positive regulation 
of c-Fes kinase domain activity by SH2 must be suppressed in the full length protein somehow. 
Intramolecular interactions involving the F-BAR and SH2 domains could explain this 
phenomenon. Unlike SH2-mediated activation, the structural basis of c-Fes inhibition is poorly 
understood. Figure 9 and the section below go into detail about this hypothetical model of c-Fes 
autoregulation. 
3.2.2 Proposed model of c-Fes autoregulation. 
The auto-stimulatory SH2-kinase domain interaction is required for upregulated activity; 
therefore a mechanism of c-Fes autoregulation is such that the F-BAR binds the SH2 region in a 
manner that is auto-inhibitory, preventing the positive regulation of the kinase by the SH2. It 
may be that the first coiled-coil of the F-BAR is essential to this. The hypothetical model 
explains the following prior observations: a) full-length, wild-type c-Fes is tightly regulated in 
vivo, assuming the inactive state (13), yet b) truncated c-Fes containing only the SH2 and kinase 
domains is constitutively active (64); c) mutation that upsets CC1 of the F-BAR results in 
uninhibited activity (46, 75), and d) SH2 replacements that lack critical, conserved residues in 
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the αB helix disinhibits c-Fes (21, 46), while e) substitution of the SH2 domain with a species 
(e.g. Ras-Gap) that bears critical dissimilarities from c-Fes in the αA helix is not active (21, 46) 
and f) SH2-deletion results in diminished activity, but not inhibition as seen in the wild-type c-
Fes (21). 
 
Figure 9. Hypothetical model of c-Fes autoregulation. The inactive (OFF) conformation of c-Fes may be such 
that the F-BAR interacts with the SH2, keeping the SH2-kinase stimulation from occurring. One way in which c-Fes 
could be turned ON would be some adapter or substrate (perhaps in complex) disrupts the F-BAR:SH2 interface, 
freeing the SH2 to cooperate with the N-lobe to promote catalytic activity. In this case, the F-BAR and CC2 could 
then participate in oligomerization that accompanies Fes activity. (Not drawn to scale or with true orientation of all 
features.) 
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3.3 SPECIFIC AIMS 
3.3.1 Test for Fes F-BAR:SH2 interaction. 
Mutagenesis studies and X-ray crystallography show that the auto-stimulatory 
SH2:kinase domain interaction is required for c-Fes kinase activity (64); therefore, the 
mechanism of c-Fes autoregulation may be that the F-BAR (in particular the CC1 domain) binds 
to the SH2 region in a manner that prevents positive regulation. This model explains why loss of 
the F-BAR or CC1 results in uninhibited activity (46, 75) and why substitution of the Fes SH2 
with that of v-Src releases kinase activity (21, 46). Based on the model, some component 
including CC1 of the N-terminal region of c-Fes interacts with the SH2-kinase region. A BiFC 
approach can test this mechanism (Figure 7). Interaction can be visualized directly and mutants 
known to deregulate Fes activity (L145P) can be compared to wild-type pairings.  
3.3.2 Develop tools to test the effect of F-BAR:SH2 interaction on Fes activity. 
The SH2 domain is required for full kinase activity and x-ray crystallography 
demonstrates that the SH2 domain interacts with the kinase domain, stabilizing a critical helix in 
the N-lobe, and promotes the active conformation of the kinase domain. Introducing mutations at 
key residues involved in the interaction of the SH2 and kinase domains revealed by the crystal 
structure results in reduced catalytic activity (64). Given that the F-BAR region interacts with the 
SH2 domain, mutations of amino acids contained within these two that increase kinase activity 
may be at the interaction interface of the F-BAR and SH2. Conversely, mutations found to 
diminish this interdomain interaction may cause upregulated catalytic activity. Substitution of the 
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Fes SH2 with that of v-Src releases Fes kinase activity in cells when wild-type c-Fes would be 
repressed. Substitution with the v-Fps SH2, however, does not affect Fes regulation. Therefore, 
differences between the c-Fes and v-Src SH2 domains not found in v-Fps may be responsible for 
the activity of the Fes/v-Src SH2 chimera. Sequence alignments and structural overlays assisted 
this comparison and reveal a few amino acid candidates for mutagenesis (see Figures 12 and 13). 
These Src-like mutations introduced into the Fes BiFC constructs allows for testing their effect 
on interdomain interaction. Mutations that diminish the F-BAR:SH2 interaction could then be 
introduced into full-length Fes for kinase activity studies. 
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4.0  EXPERIMENTATION 
4.1 F-BAR:SH2 INTERACTION DEMONSTRATED BY VENUS BIFC IN CELLS 
4.1.1 Construction of Plasmids. 
To create the vectors required for BiFC analysis, sequences encoding regions of c-Fes 
from the N-terminal region (“F-BAR”, bp 1-1053, encoding aa 1-351; “F-BAR-L”, bp 1-1341, 
encoding aa 1-447), SH2 domain (bp 1342-1653, encoding aa 448-551), kinase (“KD”, bp 1654-
2466, encoding aa 552-822), SH2-kinase core, (“SH2-KD”, bp 1342-2466, encoding aa 448-822) 
and full length c-Fes (2466 bp; 822 aa) were amplified by PCR from a pcDNA3.1(+)Fes-FLAG 
parent plasmid and subcloned into both pcDNA3.1(-)VN173 and VC155 vectors. This way each 
of the Fes cDNAs were fused to the N-terminus of both VN173 and VC155 Venus YFP 
fragments in order to perform BiFC experiments with many combinations. PCR site-directed 
mutagenesis (Stratagene QuikChange II XL) with point mutation primers (sense 5’-GC CAG  
TAC CGA GCT CCG GCA CGG GAC AGT GC-3’; antisense 5’-GC ACT GTC CCG TGC 
CGG AGC TCG GTA CTG GC-3’) generated L145P mutants of the F-BAR and F-BAR-L 
Venus constructs. Plasmids were confirmed by sequencing (Genewiz) and amplified for 
experiments by Maxiprep (Invitrogen). 
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4.1.2 Cell Culture and Transfection. 
HEK-293T cells were maintained at 37 °C in humidified incubators (5% CO2) and 
cultured in 5% FBS-supplemented DMEM (Invitrogen). Transient transfection was performed as 
follows: 293T cells (3x105) were plated in 12-well plates for BiFC (or 100 mm dishes for cell 
lysates) and transfected the next day (at 50-70% confluency) with 1 µg of total plasmid DNA—
0.5 ug of each of the two, VC and VN—delivered in 3 µl X-tremeGENE transfection reagent 
(Roche). All transfections were performed using serum-free media as diluent. Following 
incubation at 37 °C for 24 hours, transfected cells were viewed, then fixed with 4% 
paraformaldehyde and immunostained to detect expression levels (section 4.1.3, below). 
Transiently transfected 293T cells in 100 mm dishes were washed with PBS, suspended in Fes 
lysis buffer (50 mM Tris/HCl pH 7.4, 1 mM EDTA, 50 mM NaCl, 1 mM MgCl2, 0.1% Triton X-
100, 2 mM PMSF, 2 mM Na3VO4, 25 mM NaF) and sonicated for 10 sec on ice. The cell lysates 
were cleared of debris by centrifugation, mixed with 2X SDS-PAGE buffer (125 mM Tris-HCl 
pH 6.8, 20% glycerol, 4% SDS, 172 mM βME, 0.05% bromophenol blue), boiled at 95 °C for 2 
min, then separated by SDS-PAGE and transferred to PVDF membrane. Western blots were 
treated with antibodies directed against GFP or actin (1:1000, Santa Cruz), then washed and 
incubated with AP-conjugated secondary antibodies (1:10,000), in order to check for expression 
and even loading. NBT/BCIP treatment visualized these immunostained protein bands. 
4.1.3 Immunofluorescent staining. 
The transfected cells in multi-well plates were fixed with 4% PFA-PBS solution for 10 
minutes followed by washes with cold PBS and permeabilization by 0.2% Triton X-100 (in PBS) 
 38 
treatment for 15 min. Following 2% BSA-PBS blocking for 30 minutes, cells were incubated at 4 
°C overnight with anti-GFP (1:500 dilution in 2% BSA-PBS), which again recognizes both VC 
and VN fragments. Immunostained cells were visualized with Texas Red-conjugated secondary 
antibodies (1:1000) so that IF counterstain was in a distinct channel from the green BiFC.  
4.1.4 Fluorescence Microscopy and Imaging. 
Images were captured of cells using an inverted epifluorescence microscope (Nikon 
TE300) accompanied by a SPOT Advanced charge-coupled digital camera and software 
(Diagnostic Instruments). Grayscale images of both IF red- and BiFC green-channels at multiple 
spots in each well, which represent a single experimental BiFC pair, were acquired and saved as 
TIFF files for later analysis.  
4.1.5 BiFC Quantification. 
In order to collect quantifiable data for analysis and graphical representation, both IF 
(protein expression) and BiFC (interaction) images of a single spot for a given co-expression 
were opened in ImageJ software. The 100.0 rolling-ball operation automatically removes image 
background for both IF and BiFC images. Then, the threshold intensity is set on the IF image so 
that only fields (cells and cell clusters) exhibiting adequate IF (expression) are measured. The 
program can then record the mean gray value (and several other measurements) of all IF-positive 
cells/regions on the image, effectively measuring fluorescence intensity of many cells. In the 
next step, the exact same image fields and measurement parameters were applied to the 
corresponding BiFC image. This way only cells expressing the BiFC constructs were quantified, 
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eliminating false negatives. In Excel (Microsoft), all the matched IF-BiFC mean values were 
analyzed. The ratio of BiFC intensity to IF intensity indicates interaction efficiency—the extent 
to which the co-expressed VN- and VC-fused Fes domains interact and YFP complementation 
occurs. The entire data set of BiFC:IF ratios for each tested pair were averaged and the 
correlation coefficient found. BiFC as a function of IF was plotted to display correlation as the 
slope of a line fit to the scattered points of individual cells. 
4.1.6 Results. 
Previous studies suggest that deletion or mutation of the F-BAR results in a highly active 
SH2-kinase domain coupling (64, 75), so direct evidence of the F-BAR interacting with either 
the SH2 or kinase domain would be consistent with a mechanism of autoregulation. To 
determine if these domains interact, I applied a BiFC-based strategy in which complementary 
fragments of Venus YFP were fused to truncations of c-Fes containing its various domains and 
expressed in HEK-293T cells (which do not express endogenous c-Fes). Approximately 24 hours 
post-transfection, a BiFC signal was visible from c-Fes oligomerization (and GST dimerization) 
BiFC, which was expected (76).  Transfected cells in the same 12-well plates were fixed and 
immunostained for GFP, which recognizes both fragments of Venus. (The X-tremeGENE co-
transfection protocol is highly efficient and immunoblots of cell lysates confirm expression.) 
ImageJ data analysis of corresponding immunofluorescence (IF) and BiFC images generated sets 
of mean intensity values for IF-positive cells. In Figure 10 on the top left are representative 
images (pseudo-colored red and green for IF and BiFC, respectively) of equivalent exposure 
times for F-BAR-VC co-expressed with SH2-VN. (Note: a longer linker on the F-BAR may 
allow for more efficient BiFC, as the F-BAR-L construct was preferred in these experiments.) In 
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this BiFC experiment, it is clear that the F-BAR interacts with the SH2 as most cells expressing 
the two display a strong signal. The mean BiFC:IF ratios of individual cells were plotted and 
show a positive correlation between the level of expression and complementation. Compared to 
wild-type, the VC-fused L145P mutant does not produce a robust BiFC signal when co-
expressed with the SH2 domain-VN fusion. Unlike with wild-type F-BAR-VC, there is not a 
strong positive correlation (slope of the line) between the expression of this pair and BiFC. This 
greatly abated BiFC to IF ratio indicates that a mutation which kinks CC1, releasing Fes kinase 
activity, also disrupts an F-BAR:SH2 interaction. 
 
Figure 10. F-BAR interacts with SH2 domain in CC1-dependent manner. Venus BiFC expression 
constructs were co-expressed in 293T cells, which were fixed and immunostained. Immunofluorescence (IF) and 
BiFC were visualized by fluorescence microscopy. Shown (left) are representative IF and BiFC images. Grayscale 
mean pixel densities of individual IF-positive cells were measured using ImageJ. Plots (middle) and statistics were 
generated in GraphPad PRISM 5. There is a linear correlation (top right) between expression and F-BAR:SH2 
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interaction in wild-type that is abrogated in the L145P mutant. (*p < 0.0001) Expression of the individual BiFC 
members was additionally confirmed by western blot (bottom right). 
 
 Since the interaction of the SH2 and kinase domain of c-Fes are well characterized (51, 
64), the result of co-expression of the SH2-KD Venus pair was expected (Figure 11, top). Two 
domains of Fes known to associate with one another in cis also form a complex in cells. This 
result validates our approach taken to investigate Fes interdomain interaction.  
It was not known whether the N-terminal region of Fes interacted with either the SH2 or 
kinase domains, although hypothetically one or both (individually or as a contiguous unit, SH2-
KD) could have. I tested many combinations of the various regions of c-Fes (with both 
orientations of VN and VC), such as F-BAR-L-VN -VC dimers, and the kinase domain did not 
exhibit any appreciable complementation with the F-BAR region (Figure 11, bottom). It is likely 
that the SH2 is the central hub for c-Fes intramolecular interactions. 
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 Figure 11. The Fes kinase domain (KD) interacts with the SH2 domain but not the F-BAR domain. As in the 
previous figure, shown are representative IF and BiFC images pseudo-colored green and red, respectively, for 
Venus-fragment-fused Fes domain co-expressions of the  SH2 + KD and F-BAR-L + KD. Mean pixel densities were 
measured using ImageJ and analyzed in GraphPad as before. As expected (see crystal structure) there is a positive 
relationship between expression and SH2:KD interaction whereas co-expressed F-BAR-L and KD BiFC vectors 
show no appreciable complementation.*p < 0.001 
 
4.1.7 Discussion. 
The fact that the c-Fes F-BAR region interacts with its SH2 domain in cells is an 
important discovery in Fes biology. Many other non-receptor tyrosine kinases have an SH2 and 
SH3, or more, with well-known regulatory interactions. This report is the first with direct 
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evidence for the Fes SH2 interacting with any other non-catalytic domain within c-Fes. As I have 
proposed, it may be that these two domains coordinate the regulation of c-Fes by a novel 
intramolecular mechanism, supported by the results of CC1 mutation in BiFC and full-length Fes 
kinase assays. Consistent with these findings, the F-BAR region (or a portion of it) may 
sequester the SH2 domain, thus preventing its role in kinase domain stimulation. When the F-
BAR region is deleted or mutated in a way that such that it can no longer hold the SH2 domain, 
the SH2 is free to conform to the kinase core and aid in stabilizing a pro-catalytic state. If L145P 
mutant and 45 kDa SH2-kinase core proteins are constitutively active due to this loss of auto-
inhibition, then it may be that binding of adapter proteins, oligomerization, substrate recruitment, 
or another event is the trigger of c-Fes activation in physiological conditions. Oligomerization 
and subcellular redistribution indeed coincide with c-Fes autophosphorylation, perhaps preceding 
it.  
One possible alternative interpretation is that some other protein somehow regulates c-
Fes kinase activity in an F-BAR-dependent manner; however, studies in yeast indicate that c-Fes 
regulation is intrinsic, not requiring any host cell factor (46). There remain many things unknown 
about the Fes F-BAR, such as its conformation within the full-length protein, but now there is a 
more solid basis for our working model and future studies. 
4.2 DEVELOPMENT OF TOOLS TO TEST THE EFFECT OF F-BAR:SH2 
INTERACTION ON FES KINASE ACTIVITY 
The loss of F-BAR features or replacement of SH2 have profound effects on Fes activity 
(21, 64). In the case of CC1, structural predictors suggest the Fes L145P mutant loses its 
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structure (75). The results of the previous section suggest that this coiled-coil is essential to 
interaction with the SH2, which has two α-helices of its own. Having a reciprocal mutation in the 
SH2 would strengthen the case for this interaction and its role in autoregulation. Mutants of the 
SH2 are tools needed for BiFC and full-length kinase assays to better understand c-Fes 
autoregulation. 
4.2.1 SH2 sequence and structural alignments. 
In the case of the Fes/Src SH2 substitution, a conserved glutamic acid in helix A critical 
to association with the kinase domain helix C (64) might explain why this chimera was capable 
of being so highly active. The other helix (αB) of the SH2 faces away and could be involved in 
F-BAR binding. In order to determine candidate SH2 mutants for use in future experiments, I 
performed comparative amino acid sequence analysis by ClustalW (122) alignment of c-Fes, v-
Fps, v-Src, and Ras-Gap SH2 domains (in Figure 12). Furthermore, 3D structural overlays of the 
Fes versus Src SH2 domains in PyMol (Figure 13) revealed differences in the crystal structures. 
 
Figure 12. Sequence variance between c-Fes, v-Fps, v-Src, and Ras-Gap SH2 domains. Yellow 
highlight added for emphasis of critical positions on c-Fes which are identical (or similar) in v-Fps while uniquely 
variant in v-Src αB or Ras-Gap in αA.  Light blue highlight emphasizes conservation in αA between c-Fes, v-Fps, 
and v-Src lacking in Ras-Gap, which may be critical to the auto-stimulatory SH2:KD interaction; whereas red 
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highlights positions in v-Src where conservation between c-Fes and v-Fps is not shared there, which may be 
important in the auto-inhibitory F-BAR:SH2 interaction. 
 
Based on the X-ray crystallography (64) and these alignments, there are number of SH2 
mutations that can be made to probe the F-BAR:SH2 interface. Since only the v-Src SH2 
substitution leads to the active kinase, significant differences in the amino acid sequence of the 
αB helix in v-Src versus c-Fes may be responsible for the loss of inhibition. Instead of 
completely replacing the entire helix with the v-Src sequence, I designed primers to generate 
four mutants: S532A, T533A, Q534A, and triple STQ/AAA. These three residues protrude 
outward from the αB helix, and are therefore most likely to form the proposed negative 
regulatory interface with CC1. The Fes SH2 packs against the kinase N-lobe, forming a critical 
interface coordinated by polar interactions between the helix αA of the SH2 and αC of the kinase 
domain stabilized by acidic residues in the SH2 αA (E469 and E472) and αC of the kinase 
domain (R609). Therefore, these E/K mutations were part of the mutagenesis performed in this 
work in order to have well-characterized control mutations. 
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 Figure 13. Alignment of c-Fes SH2-kinase domain crystal structure with v-Src domain. Top) Full-
view of the X-ray crystal structure of the Fes SH2-kinase unit (PDB.3BKB). The Src SH2 domain (PDB:1SHB, 
orange) was aligned to the Fes SH2. The Fes SH2 (red) forms an interface with the kinase N-lobe (blue). Polar 
interactions between the helices are stabilized by E469 and R609. Bottom) Close-up view of the overlaid SH2 
domains, with the v-Src shown in orange. A stretch of three residues of helix B (STQ) are not the same in v-Src. 
Docking of the Src SH2 domain onto that of c-Fes positions a glutamate residue in the Src SH2 αB helix in close 
proximity to R609 in the Fes N-lobe helix αC. This observation suggests that the v-Src SH2 domain can still form a 
productive SH2:N-lobe interface required for kinase activity. 
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4.2.2 Site-directed mutagenesis. 
PCR site-directed mutagenesis was performed on the pcDNA3.1 Fes SH2-BiFC and a c-
Fes-FLAG plasmids with 16 primers (8 mutations) to generate 19 new constructs. Primers were 
designed to be oligomers between 20-30 bp in length, with a high GC content, melting around 80 
°C, with G/C ends, and central mismatches. The primers (sense 5’-3’): for helix B were S532A 
(C GAC CAC CTA CTG GCC ACC CAG CAG CCC C), T533A (C CAC CTA CTG AGC 
GCC CAG CAG CCC C), Q534A (C CTA CTG AGC ACC GCG CAG CCC CTC ACC), and 
STQ/AAA (C GAC CAC CTA CTG GCC GCC GCG CAG CCC CTC ACC); for helix A 
E469K (C CCG AGG GCA AAG GTG GCT GAG C), E472K (GCA GAG GTG GCT AAG 
CTG CTG GTG C), and EE/KK (CCG AGG GCA AAG GTG GCT AAG CTG CTG G); for 
kinase dead Fes, K590E (C CTG GTG GCG GTG GAG TCT TGT CGA GAG ACG). The E-K 
and K59E mutations were also introduced into L145P Fes-FLAG plasmids to test these changes 
in a Fes background that is already activated. Small-scale bacterial preparation preceded 
sequence confirmation, followed by large-scale preparations.  
 
4.2.3 Results. 
The mutations were successfully introduced into the BiFC and full-length Fes plasmids 
generating VN-SH2 S/T/Q→A, VN-SH2 E/E→K, as well as FLAG-Fes and L145P Fes 
counterparts with these mutations. Preliminary data gathered with a few of these shows that they 
can be used as tools to learn more about Fes regulation. In a BiFC experiment with the F-BAR, 
the Q534A and AAA mutants of SH2 helix B displayed extremely weak BiFC compared to the 
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wild-type SH2. However, mutation on the other side of the SH2 (αA EE/KK) did not 
significantly affect the F-BAR interaction. 
 
Figure 14. Src-like mutations in αB diminish F-BAR:SH2 BiFC. 293T cells were transfected with F-
BAR-VC and SH2-VN as before, along with wells for the SH2-VN mutants. After 24 hours of expression, fixing, 
and immunostaining 6 sec exposures were captured. Consistent with an αB:CC1 helical interaction, mutations in 
helix B seem to reduce BiFC.  
4.2.4 Discussion. 
The successful BiFC experiment verifies the utility of the SH2-VN mutants. The same 
cannot be said for the Fes-FLAG mutants as there may be stability (or expression) issues. 
Attempts at western blots, particularly for pTyr713, were highly variable. It may be more 
prudent to use YFP-Fes, as it may be more stable and more easily detected in COS-7 
experiments to observe subcellular localization and pTyr immunofluorescence. The full-length 
Fes SH2 mutants would be critical to phosphorylation activity studies of Fes with respect to the 
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hypothesis that the F-BAR inhibits the kinase by SH2 association. An experiment showing that 
the results seen in L145P mutation are similar in SH2 helix B mutants would fit in nicely. 
The preliminary result (shown in Figure 14) is consistent with the idea that the F-BAR 
interacts with the SH2 by recognizing helix B. This would explain why the v-Src SH2 chimera 
was activated while the v-Fps SH2 chimera was not. The αA mutant performed like wild-type 
when it came to F-BAR interaction, so not just any mutation of the SH2 will destabilize it. 
Future experiments might show that this EE/KK does not interact with the kinase domain as 
demonstrated by BiFC, which would be consistent with previous studies.    
4.3 FUTURE DIRECTIONS 
4.3.1 Translation of BiFC results with interdomain interaction mutants into full-length c-
Fes activity studies. 
In order to connect Fes interdomain interactions shown by BiFC to regulation of Fes 
kinase activity, the mutations that affect BiFC should be tested in full-length Fes. 
Autophosphorylation in the activation loop of Fes at tyrosine residue 713 is required for activity 
and indicates the upregulated kinase, so will serve as the primary readout of functionality. It can 
be detected by phospho-specific immunostaining of western blots or fixed cells (21, 46, 75). 
Comparison between immunoblots of lysates from cells expressing wild-type c-Fes versus Fes 
bearing mutations that have resulted in reduced BiFC between regulatory domains will clarify 
whether the intramolecular interactions are linked to catalytic activity. L145P will exemplify 
positive activity, while the K590E kinase dead mutant will serve as a negative control. 
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Constitutively active or dysregulated c-Fes has been implicated in some cancers, like AML, and 
has been shown to drive transformation in a number of cell types. As a model for transformation, 
wild-type and mutant forms of full-length Fes could be subcloned into retroviral vectors for 
transduction of rodent fibroblasts, followed by focus-forming and soft agar colony formation 
assays (21, 75). To evaluate the mutants in a context relevant to human cancer, TF-1 myeloid 
leukemia cells may be infected with retroviruses expressing mutant Fes (75). TF-1 cell-
attachment, spreading, and growth in the absence of GM-CSF would indicate downstream 
activation of survival pathways of these leukemia cells as a model for AML. RNAi knockdown 
of the mutant resulting in reversal of the effect the mutant had would serve as confirmation. This 
approach may also be applied to transformed cells stably expressing KITD816V or Flt3 (97, 98). 
These in vitro and in vivo kinase activity experiments are necessary to couple BiFC findings 
with c-Fes autoregulation. 
4.3.2 Complementary F-BAR en bloc substitution experiments. 
F-BAR domain proteins are typically thought of as regulators of membrane curvature and 
dynamics, implicated in endocytosis, exocytosis, vesicular transport, cellular morphogenesis, and 
motility (36, 43, 123, 124). However, here I present findings to implicate the Fes F-BAR in 
regulation of its catalytic function through interaction with the SH2 domain. Structural data on 
the F-BAR is pending and no crystal structure exists for full-length c-Fes, where it may be 
revealed how exactly the F-BAR interacts with the SH2 domain and what happens to the SH2-
kinase domain interaction as a consequence in the downregulated state. (There is, however, a 
recently uploaded PDB:4DYL that has resolved much of the N-terminal region of c-Fes, see 
Appendix A.) In the meantime, experiments with homologous F-BAR domains swapped in for 
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the Fes N-terminal region could be very informative, as SH2 substitution has been in the past 
(21). Closely related F-BARs include FCHSD1 and TOCA2, while more taxonomically distant 
are Pacsin1 and FCHO (43). It would be ideal to find a few homologous F-BAR domains that 
show diverse effects on the Fes kinase activity. In that way, comparison of the sequences and 
structures of these F-BAR domains might identify specific features or residues that are involved 
in Fes regulation. 
4.3.3 Development of a BiFC-based platform for c-Fes allosteric small molecule 
modulators. 
Since tyrosine kinase domains are highly conserved, inhibitors directed against the kinase 
domain often lack specificity (125). Even in cases where a relatively high level of target 
selectivity has been achieved, resistance mutations arise in patients following long-term drug 
exposure (e.g. imatinib, which inhibits Bcr-Abl in CML). In that case, combination therapy with 
allosteric inhibitors may be effective (126). In the case of Fes, novel allosteric inhibitors and 
activators that target its unique regulatory regions—SH2 interfaces with the kinase domain and 
F-BAR, respectively—represent powerful new tools in the study of c-Fes signaling pathways and 
potentially new treatments for Fes-related cancers. Due to the differing tissue-specific roles of c-
Fes in cancer, small molecule modulators of this kinase present utility in both investigation of its 
function and anti-cancer therapy. The BiFC strategy developed for investigating interdomain 
interactions of c-Fes could be adapted to identify allosteric small molecule modulators of c-Fes 
activity (Figure 15). An advantage of a BiFC-based screen is that it occurs in a mammalian 
cellular context. The ArrayScan II (Thermo Scientific) can be adapted to BiFC in an 384-well 
format. The BiFC pair to be screened against, either F-BAR:SH2 or SH2:kinase domain, would 
 52 
be expressed from a single 2A plasmid. Self-cleaving viral 2A sequences (127) separate the two 
BiFC-fragment-fused domains and a marker RFP gene so that the BiFC pair will be expressed in 
equimolar quantities. Thus, ArrayScanII can identify expression-positive cells, which will be 
gated on the RFP signal. This 2A-BiFC expression platform has been successfully developed by 
our laboratory as a screening assay for small molecules interfering with HIV Nef 
homodimerization with a Z'-factor of ~0.7, which is indicative of a robust screening assay (J Poe 
& T Smithgall, manuscript submitted). In the case of the Fes screen, the wild-type F-BAR-
VC:SH2-VN BiFC pair, expressed in the absence of library compounds (DMSO present), and 
BiFC-negative F-BARL145P-VC:SH2-VN transfections will serve as plate controls to define the 
screening window on each plate. For the SH2-kinase pairing, the E469K mutant may be an 
acceptable negative control. To find small molecules that act on the non-catalytic regulatory 
domains of c-Fes, one might screen the National Cancer Institute Diversity Set III library, 
ChemDiv Targeted Diversity Peptidomimetic collection, or some other set of compounds with 
highly diverse scaffolds (not designed for kinases). Chemical compounds may be auto-
fluorescent, so initial hits will be added to wells containing cells transfected with YFP only to 
identify such compounds. The goal of the screen is to identify small molecules that specifically 
target the domains of Fes, and not the BiFC reporter directly. Therefore, tentative hit compounds 
will also be counter-screened against an irrelevant GST-BiFC dimer. The GST-BiFC 
counterscreen will eliminate any compounds that artificially quench BiFC without actually 
binding Fes. Once false-positive and nonspecific compounds are sorted out, one might perform 
10-point concentration-response experiments with the true hits in the same BiFC assay used in 
the primary screen to determine the most effective concentration for use in secondary activity-
based screens. Lead candidates will be small molecules that most effectively alter BiFC at the 
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lowest concentration. Hits will be prioritized further based on cytotoxicity, where the drugs least 
toxic to mammalian cells will be preferred and tested for effects on activity of the full-length 
Fes. Secondary screens would involve full-length c-Fes and appropriate control mutants—L145P 
activated and K590E kinase dead mutants—to be assayed for kinase activity by Rat-2 
transformation in the presence of candidate small molecule modulators. The readout will be 
colony-forming activity, correlated with Fes kinase activity by pY713 immunoblotting. Hits that 
reduce F-BAR:SH2 BiFC would be c-Fes activators. In contrast, small molecules reduce 
SH2:kinase domain BiFC would be inhibitors. 
 
Figure 15. BiFC-based screen concept for allosteric modulators of Fes activity. I) In DMSO-only wells, the 
interacting partners generate a normal BiFC signal for that pairing. II) In the presence of a small molecule activator 
of Fes, the BiFC between F-BAR and SH2 would be reduced. III) In the case of an inhibitor, the SH2-kinase domain 
BiFC would be impaired. (Not drawn to scale or with true orientation of all features.) 
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APPENDIX A 
SUPPLEMENTAL FIGURES 
 
Supplemental Figure 1. First X-ray diffraction crystal structure of human FES F-BAR. Shown are 
residues 1-405 of c-Fes. FCH and CC1 (green) make up the F-BAR, while CC2 and linker segments (gray) were 
also resolved to within 2.18Å. The leucine at position 145 (cyan) is highlighted for reference as proline substitution 
is predicted to kink CC1. (PDB:4DYL; Ugochukwu, E.,  Salah, E.,  Elkins, J.,  Barr, A.,  Krojer, T.,  P.,  
Filippakopoulos, Weigelt,  J.,  Arrowsmith, C.H.,  Edwards, A.,  Bountra, C.,  von Delft, F.,  Knapp, S.,  Structural 
Genomics Consortium, publication pending) 
Since crystal structures of both the F-BAR region and the SH2-kinase core have been 
solved, and BiFC captures the F-BAR:SH2 interaction, it may be plausible to try co-
crystallization of F-BAR and SH2 or SH2-kinase complexes. In silico binding and folding 
analysis may predict the conformation of the Fes F-BAR in complex with the SH2 and kinase 
domains. 
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